Dataset from Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh

The main objective of this study is to provide immunogenicity data for GSK Biologicals' HRV vaccine when co-administered with OPV or when given alone (HRV vaccine dose given 15 days after the OPV dose).

本研究的核心目标是为葛兰素史克生物制品公司（GSK Biologicals）的轮状病毒疫苗（HRV vaccine）提供免疫原性数据，该疫苗可与口服脊髓灰质炎减毒疫苗（Oral Polio Vaccine，OPV）联合接种，亦可单独接种；若采用单独接种方案，则需在口服脊髓灰质炎减毒疫苗接种完成15天后，给予对应剂量的轮状病毒疫苗。